EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeted gene therapy for rare genetic kidney diseases

Veenita Khare, Stephanie Cherqui

Kidney International · 2024-12 · 106 (6) · 1051-1061

DOI: 10.1016/j.kint.2024.07.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2024-12. Verfasst von Veenita Khare und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: California Institute of Regenerative Medicine, Cystinosis Research Foundation, California Institute for Regenerative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease is one of the leading causes of mortality worldwide because of kidney failure and the associated challenges of its treatment including dialysis and kidney transplantation. About one-third of chronic kidney disease cases are linked to inherited monogenic factors, making them suitable for potential gene therapy interventions. However, the intricate anatomical structure of the kidney poses a challenge, limiting the effectiveness of targeted gene delivery to the renal system. In this review, we explore the progress made in the field of targeted gene therapy approaches and their implications for rare genetic kidney disorders, examining preclinical studies and prospects for clinical application. In vivo gene therapy is most commonly used for kidney-targeted gene delivery and involves administering viral and nonviral vectors through various routes such as systemic, renal vein, and renal arterial injections. Small nucleic acids have also been used in preclinical and clinical studies for treating certain kidney disorders. Unexpectedly, hematopoietic stem and progenitor cells have been used as an ex vivo gene therapy vehicle for kidney gene delivery, highlighting their ability to differentiate into macrophages within the kidney, forming tunneling nanotubes that can deliver genetic material and organelles to adjacent kidney cells, even across the basement membrane to target the proximal tubular cells. As gene therapy technologies continue to advance and our understanding of kidney biology deepens, there is hope for patients with genetic kidney disorders to eventually avoid kidney transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyGenetic VectorsHumansAnimalsRenal Insufficiency, ChronicGene Transfer TechniquesRare DiseasesKidneyKidney Diseases

Stichwörter der Autor:innen

adeno-associated viral (AAV) vectorex vivo gene therapyhematopoietic stem and progenitor cellsin vivo gene therapylentiviral vectorlipid nanoparticles

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, California, USA.
  • Department of Pediatrics, Division of Genetics, University of California, San Diego, La Jolla, California, USA. Electronic address: scherqui@ucsd.edu.

Förderung

  • California Institute of Regenerative Medicine
  • Cystinosis Research Foundation
  • California Institute for Regenerative Medicine
  • National Institutes of Health

Zitieren

APA

Khare, V., & Cherqui, S. (2024). Targeted gene therapy for rare genetic kidney diseases. Kidney International, 106(6), 1051-1061. https://doi.org/10.1016/j.kint.2024.07.034

Vancouver

Khare V, Cherqui S. Targeted gene therapy for rare genetic kidney diseases. Kidney International. 2024;106(6):1051-1061. doi:10.1016/j.kint.2024.07.034

BibTeX
@article{Khare2024,
  author = {Khare, Veenita and Cherqui, Stephanie},
  title = {Targeted gene therapy for rare genetic kidney diseases},
  journal = {Kidney International},
  year = {2024},
  volume = {106},
  number = {6},
  pages = {1051--1061},
  doi = {10.1016/j.kint.2024.07.034}
}
Kostenlos starten →